• Monte Rosa outlined plans to start Phase 2 trials in 2026 for three molecular glue degrader programs, including VAV1 degrader MRT-6160, NEK7 degrader MRT-8102, and GSPT1 degrader MRT-2359.
• Pipeline update flagged Phase 2 initiation for MRT-8102 in Q3 2026, with Phase 1 data for MRT-2359 followed by Phase 2 initiation in H2 2026.
• Additional wholly owned IND submissions targeted for H2 2026, including CCNE1 MGD, with further INDs anticipated over next two years.
• Collaboration economics highlighted USD 350 million received in collaboration payments over last three years, with potential for more than USD 400 million over next 24 months.
• Balance sheet commentary pointed to cash runway into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.